Gilead Increases Its Remdesivir Donation To U.S. As Executives Tout Drug’s Long-Term Profit Potential
The drugmaker didn't provide an explanation of why it was increasing the donation of its medication that has shown to help treat coronavirus patients. Meanwhile, Gilead seems eager to convince skeptical investors that the $1 billion spent this year on development and production can eventually yield a real return.